From public research to business innovation!

Predictive test of the response to anti-TNFα treatment

Domain Health and wellbeing

Technology Metaomic

Applications

  • Microbiota biomarker to predict positive response to anti-TNFα treatment
  • Ankylosing spondylitis, Crohn's disease, ulcerative colitis anti-TNF therapy
  • Other inflammatory diseases such as psoriasis, rheumatoid arthritis, psoriatic arthritis,, for which anti-TNF therapy is prescribed.

Description

Although effective in blocking the mechanisms of chronic rheumatic inflammation, anti-TNF are expensive biotherapies that may present infectious risks. They are therefore prescribed after observation and in 2nd line after NSAIDs and failure of methotrexate.

This technology is a test which detects a level of expression of burkholderia bacteria  in the microbiota of patients with Ankylosing spondylitis, Ulcerative colitis and Crohn disease for earlier and more efficient treatment with anti-TNF.

Benefits

  • Adapted anti -TNF therapy
  • Predictive efficacy
  • Earlier prescription
  • Adverse effets preservation for non-responding patients
  • Customized dosage
  • Reduced cost of disease management (for
    non-responding patients, and in general with reduction on NSAID consumption)

Inventors

Pr Thierry SCHAEVERBEKE

Head of the Rheumatology department

Bordeaux University Hospital Center

Medical coordinator of ACRONIM

Contact

Jean-Luc Chagnaud

%6a%6c%2e%63%68%61%67%6e%61%75%64%40%61%73%74%2d%69%6e%6e%6f%76%61%74%69%6f%6e%73%2e%63%6f%6d